Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...

CAR T-cell therapy is starting to enter the treatment conversations sooner with patients with multiple myeloma, according to ...

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

"Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma" was originally created and published by ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood cells that produce infection-fighting antibodies. Multiple myeloma is not hereditary, meaning it is not passed ...

Multiple myeloma (MM) is caused by the clonal expansion of plasma cells in the bone marrow. While survival from MM has improved significantly over the last decade with the introduction of ...

Indapta has amended its ongoing phase 1 study of IDP-023, to add a cohort of IDP-023 in combination with Sarclisa for patients with relapsed/refractory multiple myeloma.

This appears to be superior to prior trials of natural killer cells in myeloma. “With its deep experience in multiple myeloma and pipeline of products in hematologic malignancies and immunologic ...

Researchers have made a significant discovery that could one day help tailor immunotherapy treatments for patients with multiple myeloma, a type of blood cancer. The findings suggest that an ...

Multiple myeloma is a type of blood cancer that appears mainly after the age of sixty. Its incidence, therefore, increases with the aging of the population. Today, an article published in the journal ...